Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore.
The post UPMC Enteprises’ Biopharma Lead: We are At a Tipping Point When it Comes to China appeared first on MedCity News.
